US/UK/Canada

Share

Contacts

  • VibroSense Dynamics AB
    VibroSense Dynamics AB Medeon Science Park, Per Albins väg 41, 205 12, MALMÖ
    +46 40 88 026
    http://www.vibrosense.com
    • Pick a time period -
    Tags ( Active)

    New Research: Diabetic Neuropathy Can Be Reversed?

    New research published in the Journal of the Peripheral Nervous System (Sloan et al., 2026) shows that the understanding of peripheral nerve damage caused by diabetes (DPN) is shifting. DPN has long been regarded as irreversible, but a growing number of studies suggest that nerve damage can be reversed, especially if the condition is detected early.The current publication provides a review of research both supporting and opposing the possibility of reversing diabetes-related nerve damage. The researchers’ key message in favour of reversibility is that it depends on timing. Early nerve

    Receives regulatory approval in Singapore

    VibroSense Dynamics AB (publ) announces today that VibroSense Meter® II has received regulatory approval in Singapore, listed as a Class A medical device with the Health Sciences Authority (HSA). The approval marks an important milestone in VibroSense’s expansion into the Asia-Pacific region.Singapore is one of Asia’s leading medical technology hubs, known for its stringent regulatory standards and world-class healthcare system. The country serves as a strategic gateway to the broader Southeast Asian market, with a strong infrastructure for medical device distribution and a growing focus on

    Signs Distribution Agreement with Sparqmed in Poland

    VibroSense Dynamics AB (publ) announces today that a distribution agreement has been signed with Sparqmed, a newly started medical device distributor based in Warsaw, Poland. The agreement grants Sparqmed the right to market and sell VibroSense products in the Polish market.Poland is an important market with significant potential in diabetes care and occupational health. The country has over 3 million diagnosed diabetics and a growing awareness of the need for early neurological diagnostics. The agreement with Sparqmed is a step in VibroSense continued European expansion.   Poland

    Signs Distribution Agreement with Alpmed in Turkey

    VibroSense Dynamics AB (publ) announces today that the company has signed a distribution agreement with Alpmed Tibbi Cihazlar, a medical device distributor active in the Turkish market. The agreement grants Alpmed the right to market and sell VibroSense products in Turkey, marking the company’s entry into the Turkish market.Alpmed Tibbi Cihazlar is an established medical device distributor in Turkey with strong knowledge of the Turkish healthcare system and its procurement processes. Turkey is one of Europe’s and the Middle East’s most dynamic healthcare markets, with a population of over

    Granted Patent in Japan - Biomarker for prediction of chemotherapy induced peripheral neuropathy

    VibroSense Dynamics AB (“VibroSense”) has been granted a patent in Japan on a Biomarker to predict the risk of developing permanent nerve damage caused by chemotherapy (CIPN) at treatment of cancer.The granted patent claims in Japan correspond to those previously granted by the European Patent Office (EPO). The patent strengthens the company’s intellectual property protection and complements existing safeguards including encrypted algorithms in the software of the company’s hand and foot instruments.“It is well known that the nervous system is affected by chemotherapy, with a significant

    Begins research collaboration with the University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust in the UK

    VibroSense Dynamics AB (publ) has signed a tripartite research agreement with the University of Sheffield  and Sheffield Teaching Hospitals NHS Foundation Trust  . The collaboration agreement concerns a research study that aims to evaluate a new treatment to relieve pain in patients with diabetes, so-called painful diabetic neuropathy (pDPN). The study will use the VibroSense Meter® II together with other methods to evaluate the treatment effect and to identify patients who may respond well to the treatment.The study is planned to

    VibroSense continues its international market establishment

    During the fall of 2025, the company has accelerated its international launch of the medical device  product VibroSense Meter®II. Significant progress has been made on several fronts, from contacts with potential distributors to research within the prioritized segments, diabetes, oncology and occupational healthcareThe company has updated its strategy for Europe and Asia and adjusted its business model to better meet new market demands and needs. In Asia, the company is investing in distributors and in Europe, the focus is on selling to end customers and research projects.An extensive

    VibroSense Dynamics announces delayed deliveries to China

    The first delivery of VibroSense Meter II instruments to China is delayed to the spring of 2026 due to organizational changes and uncertainties at VibroSense’s distributor UMCare in China. The binding distribution agreement with UMCare remains in force; however, it will not generate previously anticipated revenues during the autumn of 2025.“We continue to see significant opportunities in China, where both research and clinical activity within the field of diabetes are strong. The diabetes market in China is huge, and there is a substantial need for improved diagnostic tools for diabetic

    Interim report 5 for the period 1 July 2025 - 30 September 2025

    With “the Company” or “VibroSense” is meant VibroSense Dynamics AB (publ) with registration number 556669–2223. Amounts in parentheses in this report refer to the corresponding period of the previous year. The Company previously applied a broken financial year until the last Annual General Meeting, at which it was decided to change the Company’s financial year from a broken fiscal year (1 July – 30 June) to a calendar year (1 January – 31 December). Therefore, the current financial year will cover a period of 18 months (6 quarters) and extend until 31 December 2025. Fifth quarter (2025-

    Newsletter – VibroSense Dynamics AB strengthens its organisation and prepares for launch in China

    VibroSense Dynamics AB (publ) enters the autumn with a strengthened organisation, new patent advancements, and preparations for the launch of VibroSense Meter® II in China.On September 1st, company co-founder Toni Speidel assumed the role of CEO. Simultaneously, the marketing and sales team was strengthened with the addition of two new Marketing & Sales Specialists. To further support the company’s expansion in China, a local Key Account Manager has also been appointed for the Chinese market.In May, the VibroSense Meter® II received approval from China's National Medical Products

    Obtains patent on Biomarker to predict the risk of getting nerve damage during cancer treatment with chemotherapy

    VibroSense Dynamics AB (“VibroSense”) has received an Intention to Grant from the European Patent Office (EPO) regarding a patent on a Biomarker to predict the risk of developing permanent nerve damage after cancer treatment with chemotherapy.The biomarker is expected to pave the way for reducing the degree of Chemotherapy-Induced Peripheral Neuropathy (CIPN), which is a common complication of cancer treatment with chemotherapy, especially in the treatment of breast, lung and colorectal cancer.The patent covers both the device and the method and strengthens the company's IP (Intellectual

    VibroSense receives a formal NMPA certificate – three-year agreement with UMCare worth 3.74 million euros enters into force

    VibroSense Dynamics AB (publ) announces today that the company has received the official certificate from the Chinese pharmaceutical authority NMPA (National Medical Products Administration). The company had previously informed the market that the NMPA approval had been granted, and with the formal certificate in hand, the three-year commercial agreement with the exclusive Chinese partner UMCare now comes into effect.The agreement, which has a total value of approximately EUR 3.74 million, covers the launch, marketing and sales of VibroSense products in the Chinese market. The

    VibroSense Dynamics enters research collaboration with Complutense University of Madrid

    VibroSense Dynamics AB (publ) has signed a research agreement with the renowned Diabetic Foot Unit at the Complutense University of Madrid. The purpose of the collaboration is to validate the VibroSense Meter® II in clinical practice and to objectively compare the technology with current standard methods used to diagnose diabetic neuropathy.The clinical study will be conducted within the framework of the Diabetic Foot Unit, a globally recognized institution with deep expertise in diabetes-related complications, including peripheral neuropathy and diabetic foot ulcers. – This

    VibroSense Dynamics AB Receives NMPA Approval for VibroSense Meter® II in China

    VibroSense Dynamics AB (publ) announces today that its medical device, VibroSense Meter® II, has been approved by the National Medical Products Administration (NMPA) in China.The approval marks a significant milestone in VibroSense Dynamics’ global growth strategy and opens up new business opportunities in one of the world's fastest-growing medical technology markets. China currently has over 140 million people living with diabetes, creating a massive need for early diagnosis and monitoring of peripheral nerve damage – an area where VibroSense Meter® II offers unique diagnostic precision.

    European patent registered

    VibroSense Dynamics AB has received a European patent on a principle that measures skin temperature automatically and wirelessly, before and during an examination, which ensures measurement quality. The patent is a so-called European patent (Unitary Patent) which has been extended by two additional countries.A Unitary Patent in the EU provides protection in Austria, Belgium, Bulgaria, Denmark, Estonia, Finland, France, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Portugal, Romania, Slovenia, Sweden and Germany. In addition to these countries, the patent has also been

    QST Technologies – New distributor in Singapore and Hong Kong

    VibroSense Dynamics AB has signed a distributor agreement with QST Technologies in Singapore and Hong Kong. The agreement allows QST Technologies to market and sell the VibroSense Meter ®II in Singapore and Hong Kong within the product's application areas.QST Technologies has also received a first order for delivery to the Duchess of Kent Children's Hospital at Sandy Bay which is a new customer in Hong Kong. The agreement with QST is a non-exclusive distributor agreement that applies to Singapore and Hong Kong but not to China “Mainland” where UMCARE has an exclusive distributor rights

    Regulatory approval in China – Supplement reply submitted

    VibroSense Chinese distributor UMCARE has submitted a supplementary response to the Chinese regulatory authority NMPA. Provided that the NMPA approves the company's application, the regulatory approval is expected to be completed in April 2025.“I am very hopeful that UMCARE's response to the NMPA will take us all the way to regulatory approval in China. It has required an extensive effort from both UMCARE and VibroSense and now I hope that we will soon reap the fruits of this work. Once the certificate is in place, the next phase of launching Diabetic Foot Screening in China will begin,"

    LifeMed Oy – New Distributor in Finland

    VibroSense Dynamics AB has signed an agreement with LifeMed OY in Finland. The agreement allows LifeMed OY to market and sell VibroSense Meter II in Finland within the product's application areas.“We are excited to have started this cooperation with LifeMed in the Finnish market. VibroSense Meter II has a wide range of applications and we look forward to offering our solutions in Finland together with LifeMed”, says Tarik Cengiz, CEO of VibroSense Dynamics AB. ContactTarik Cengiz, CEO VibroSense Dynamics ABTel: +46 40 88 026E-mail: info@vibrosense.comwww.vibrosense.com"The new

    New CEO takes office today

    Tarik Cengiz takes office today as the new CEO of VibroSense Dynamics, which is part of strengthening the organization with a focus on distributors and OEM customers.Tarik Cengiz will work on developing existing partnerships in the company's current markets. He will also put a lot of focus on driving a geographic expansion and increased sales by addressing potential international partners such as distributors, agents or OEM partners. "I would like to warmly welcome Tarik to VibroSense, both I and the board look forward to working together with him when VibroSense now clearly focuses on

    Receives a new patent in the EU

    VibroSense Dynamics AB has received a so-called "Intention To Grant" on its patent application in the EU, which strengthens the protection for the product VibroSense Meter® II. The patent describes a principle for measuring skin temperature wirelessly before and during an examination, which ensures measurement quality.The patent was approved in Sweden in November 2020 and in April in China, and after an international application, the company has now been informed that the patent will be approved in the EU. After that, a process for national applications begins throughout the EU. The company

    Strengthens the organization with a new CEO

    VibroSense Dynamics strengthens the organization by recruiting Tarik Cengiz as new CEO. Tarik will start his position as CEO on September 16, 2024 after he leaves his previous position as Global Sales Director at Arcoma AB.Tarik Cengiz will work with developing existing partnerships in the company's current markets. He will also put a lot of focus on driving a geographic expansion and increased sales by addressing potential international partners such as distributors, agents or OEM partners.Tarik has deep knowledge of how healthcare works, both in Sweden and internationally. He also has

    Regulatory approval in China is delayed 4 months

    The last and final step in obtaining regulatory approval of the VibroSense Meter ® II in China is delayed approximately four months. The delay is due to that VibroSense's Chinese distributor UMCARE has received many questions on its application, from the Chinese regulatory authority NMPA. According to UMCARE, the NMPA requires an extra careful review because there is no similar instrument in China, which is considered to be an advantage when the product is ready for launch in China. The regulatory approval is now estimated by UMCARE to be obtained at the end of April 2025 compared to their

    Investment after the completion of the new share issue

    VibroSense gains new momentum after the completion of the new share issue and increases investment in existing markets. At the same time, the company plans to gear up with more activities to reach out to new countries and thereby accelerate the company's sales.VibroSense will mainly focus the use of the issue proceeds in the areas of sales and marketing, which is completely in line with what was communicated before the recently concluded new share issue.OrganizationThe company will strengthen its own organization in the area of sales, but also take new approaches with foreign partners

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe